Diagnosing heart failure with preserved ejection fraction
Standard
Diagnosing heart failure with preserved ejection fraction. / Becher, Peter Moritz; Lindner, Diana; Fluschnik, Nina; Blankenberg, Stefan; Westermann, Dirk.
in: Expert opinion on medical diagnostics, Jahrgang 7, Nr. 5, 09.2013, S. 463-474.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Diagnosing heart failure with preserved ejection fraction
AU - Becher, Peter Moritz
AU - Lindner, Diana
AU - Fluschnik, Nina
AU - Blankenberg, Stefan
AU - Westermann, Dirk
PY - 2013/9
Y1 - 2013/9
N2 - INTRODUCTION: Heart failure with preserved ejection fraction (HFPEF) is a common syndrome, accounting for about 50% of all patients with heart failure (HF). Morbidity and mortality are similar to patients with HF with reduced ejection fraction (HFREF), yet no effective treatment has been identified in randomized clinical trials.AREAS COVERED: This article provides an overview of the available literature regarding diagnosing established HFPEF and potential new therapeutic targets for the early diagnosis of HFPEF. Vascular dysfunction, ventricular-arterial coupling, oxidative stress, extracellular matrix regulation, chronotropic incompetence, pulmonary hypertension, exercise testing and biomarkers were taken into consideration next to conventional measurements of diastolic dysfunction.EXPERT OPINION: Measuring diastolic dysfunction in HFPEF is considered important in many patients. Nevertheless, today we know that other causes besides diastolic dysfunction are also involved in the pathophysiology of many HFPEF patients and need to be investigated in order to make a correct diagnosis. Therefore, further research is required to allow better and more specific diagnostic and treatment options to reduce the morbidity and mortality for this ever-expanding HF population.
AB - INTRODUCTION: Heart failure with preserved ejection fraction (HFPEF) is a common syndrome, accounting for about 50% of all patients with heart failure (HF). Morbidity and mortality are similar to patients with HF with reduced ejection fraction (HFREF), yet no effective treatment has been identified in randomized clinical trials.AREAS COVERED: This article provides an overview of the available literature regarding diagnosing established HFPEF and potential new therapeutic targets for the early diagnosis of HFPEF. Vascular dysfunction, ventricular-arterial coupling, oxidative stress, extracellular matrix regulation, chronotropic incompetence, pulmonary hypertension, exercise testing and biomarkers were taken into consideration next to conventional measurements of diastolic dysfunction.EXPERT OPINION: Measuring diastolic dysfunction in HFPEF is considered important in many patients. Nevertheless, today we know that other causes besides diastolic dysfunction are also involved in the pathophysiology of many HFPEF patients and need to be investigated in order to make a correct diagnosis. Therefore, further research is required to allow better and more specific diagnostic and treatment options to reduce the morbidity and mortality for this ever-expanding HF population.
KW - Heart Failure/diagnosis
KW - Heart Function Tests
KW - Humans
KW - Stroke Volume/physiology
U2 - 10.1517/17530059.2013.825246
DO - 10.1517/17530059.2013.825246
M3 - SCORING: Review article
C2 - 23930995
VL - 7
SP - 463
EP - 474
IS - 5
ER -